IL321433A - 2,6,9-trisubstituted purines - Google Patents

2,6,9-trisubstituted purines

Info

Publication number
IL321433A
IL321433A IL321433A IL32143325A IL321433A IL 321433 A IL321433 A IL 321433A IL 321433 A IL321433 A IL 321433A IL 32143325 A IL32143325 A IL 32143325A IL 321433 A IL321433 A IL 321433A
Authority
IL
Israel
Prior art keywords
amino
alkyl
purin
group
ethyl
Prior art date
Application number
IL321433A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL321433A publication Critical patent/IL321433A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (23)

272 What is claimed is:
1. A compound having the structure of Formula (I): (I), or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of C1-6-alkyl, halo-C1-6-alkyl, and cyclopropyl; R is selected from the group consisting of -NHR, , and ; one of R and R is hydrogen and the other of R and R is selected from the group consisting of hydrogen, halogen, C1-3-alkyl, halo-C1-3-alkyl, and C1-3-alkoxy; R is selected from the group consisting of C1-6-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from halogen and C1-3-alkoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more substituents independently selected from C1-3-alkyl; R is C1-10-alkyl or , wherein the C1-10-alkyl is substituted with hydroxy or oxo, and is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl; 273 R is hydrogen or C1-3-alkyl; R is hydrogen; and R is selected from the group consisting of hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen; or R and R together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered saturated monocyclic ring wherein the remaining ring atoms are carbon atoms, and wherein the monocyclic ring is optionally substituted with one or more substituents independently selected from halogen.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula (I-A): (I-A), and wherein R, R, R, R, and R are as defined in claim 1.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of C1-3-alkyl and halo-C1-3-alkyl.
4. The compound of any of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is -NHR.
5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is C1-10-alkyl, wherein the C1-10-alkyl is substituted with hydroxy, and is optionally substituted with 274 one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl.
6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy.
7. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is .
8. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of , , , and .
9. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is , wherein: R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; and 275 R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl.
10. The compound of any of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R and R are each hydrogen.
11. The compound of any of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R is -NRR; R is hydrogen; and R is selected from the group consisting of hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen.
12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R is C1-6-alkyl, wherein the C1-6-alkyl is optionally substituted with one or more substituents independently selected from halogen.
13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure selected from the group consisting of: N NN NRR NHNSOO R (I-1) (I-2) (I-3) N NN NRR NHNSOO R (I-4) (I-5) (I-6) 276 (I-7) (I-8) (I-9) (I-10) (I-11) (I-12) (I-13) (I-14) (I-15) (I-16) (I-17) (I-18) 277 (I-19) (I-20) (I-21) (I-22) (I-23) (I-24) (I-25) (I-26) (I-27) (I-28) (I-29) (I-30) 278 (I-31) (I-32) (I-33) (I-34) (I-35) (I-36) (I-37) (I-38) (I-39) (I-40) (I-41) (I-42) (I-43) (I-44) (I-45) 279 (I-46) (I-47) (I-48) (I-49) (I-50) (I-51) (I-52) (I-53) (I-54) (I-55) (I-56) (I-57) (I-58) (I-59) (I-60) 280 (I-61) (I-62) (I-63) (I-64) (I-65) (I-66) (I-67) (I-68) (I-69) (I-70) (I-71) (I-72) (I-73) (I-74) (I-75) 281 (I-76) (I-77) (I-78) (I-79) (I-80) (I-81) (I-82) (I-83) (I-84) (I-85) (I-86) (I-87) (I-88) (I-89) (I-90) 282 (I-91) (I-92) (I-93) (I-94) (I-95) (I-96) (I-97) (I-98) (I-99) (I-100) (I-101) (I-102) 283 (I-103) (I-104) (I-105) (I-106) (I-107) (I-108) (I-109) (I-110) (I-111) (I-112) (I-113) (I-114) 284 (I-115) (I-116) (I-117) wherein, as applicable: R is selected from the group consisting of C1-6-alkyl, halo-C1-6-alkyl, and cyclopropyl; R is selected from the group consisting of -NHR, , and ; one of R and R is hydrogen and the other of R and R is selected from the group consisting of hydrogen, halogen, C1-3-alkyl, halo-C1-3-alkyl, and C1-3-alkoxy; R is selected from the group consisting of C1-6-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from halogen and C1-3-alkoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more substituents independently selected from C1-3-alkyl; R is C1-10-alkyl or , wherein the C1-10-alkyl is substituted with hydroxy or oxo, and is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen or C1-3-alkyl; 285 R is hydrogen; R is selected from the group consisting of hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen; or R and R together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered saturated monocyclic ring wherein the remaining ring atoms are carbon atoms, and wherein the monocyclic ring is optionally substituted with one or more substituents independently selected from halogen; R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl; and R is selected from the group consisting of hydrogen and C1-3-alkyl.
14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, and cyclopropyl; R is -NHR; R is hydrogen and R is selected from the group consisting of hydrogen and C1-3-alkyl; or R is hydrogen and R is selected from the group consisting of hydrogen, halogen, and C1-3-alkyl; R is selected from the group consisting of C1-6-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from halogen and C1-3-alkoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more substituents independently selected from C1-3-alkyl; 286 R is C1-10-alkyl, wherein the C1-10-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen; R is selected from the group consisting of hydrogen, C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen; or or R and R together with the nitrogen atom to which they are attached form an azetidinyl ring, and wherein the azetidinyl ring is optionally substituted with one or more substituents independently selected from halogen; R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl; and R is selected from the group consisting of hydrogen and C1-3-alkyl.
15. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of C1-3-alkyl and fluoro-C1-3-alkyl; R is -NHR; R is hydrogen and R is selected from the group consisting of hydrogen and methyl; or R is hydrogen and R is selected from the group consisting of hydrogen, fluoro, and methyl; R is selected from the group consisting of C1-3-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from fluoro and methoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more methyl; 287 R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen; R is selected from the group consisting of hydrogen, C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl; wherein the C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl are optionally substituted with one or more substituents independently selected from halogen; R is selected from the group consisting of C1-3-alkyl, fluoro-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkylmethyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl; and R is selected from the group consisting of hydrogen and C1-3-alkyl.
16. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of C1-3-alkyl and fluoro-C1-3-alkyl; R is -NHR; R is selected from the group consisting of hydrogen and fluoro; R is hydrogen; R is selected from the group consisting of C1-3-alkyl, cyclopropyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and cyclopropyl are optionally substituted with one or more substituents independently selected from fluoro and methoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more methyl; R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C3-6-cycloalkyl, and tetrahydrofuranyl; 288 R is hydrogen; R is selected from the group consisting of hydrogen, C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl; wherein the C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl are optionally substituted with one or more fluoro; R is selected from the group consisting of methyl, ethyl, fluoroethyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and methyl; and R is selected from the group consisting of hydrogen, methyl, and fluoromethyl.
17. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of methyl, ethyl, isopropyl, fluoromethyl, and difluoromethyl; R is -NHR; R and R are hydrogen; R is selected from the group consisting of methyl, fluoromethyl, trifluoromethyl, methoxyethyl, cyclopropyl, -NRR, imidazolyl, pyrazolyl, methylimidazolyl, and methylpyrazolyl; R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen; R is selected from the group consisting of of hydrogen, methyl, ethyl, difluoroethyl, trifluoroethyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl; R is selected from the group consisting of methyl, ethyl, fluoroethyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and methyl; and 289 R is selected from the group consisting of hydrogen, methyl, and fluoromethyl.
18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: (S)-3-((9-ethyl-2-(1-oxoisoindolin-4-yl)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-((R)-1-hydroxy-2,3-dihydro-1H-inden-4-yl)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-((R*)-1-hydroxy-1-methyl-2,3-dihydro-1H-inden-4-yl)-9H-purin-6-yl)-amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-sulfonamide; (S)-N-(2,2-difluoroethyl)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((S)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)-pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2S,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)-amino)pyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2S,3R)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)-amino)pyrrolidine-1-sulfonamide; 290 (S)-N-ethyl-3-((9-ethyl-2-(((R)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2R,3R)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-3-((2-(((R)-1-cyclopropyl-2-hydroxyethyl)amino)-9-(difluoromethyl)-9H-purin-6-yl)-amino)-N-ethylpyrrolidine-1-sulfonamide; 2-cyclopentyl-2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)ethan-1-ol; 2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-2-(tetrahydrofuran-2-yl)ethan-1-ol; (R)-2-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoropyrrolidin-3-yl)amino)-9-ethyl-9H-purin-2-yl)amino)-2-cyclopropylethan-1-ol; (S)-3-((2-(((2S,3R)-1,3-dihydroxybutan-2-yl)amino)-9-ethyl-9H-purin-6-yl)amino)-N-((R)-tetrahydrofuran-3-yl)pyrrolidine-1-sulfonamide; (S)-3-((2-(((R)-1-cyclopropyl-2-hydroxyethyl)amino)-9-methyl-9H-purin-6-yl)amino)-N-ethylpyrrolidine-1-sulfonamide; (R)-2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)-amino)-9H-purin-2-yl)-amino)-3-methylbutan-1-ol; (S)-3-((9-ethyl-2-(((3S,4R)-1,1,1-trifluoro-4-hydroxypentan-3-yl-)-amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-((S)-tetrahydrofuran-3-yl)pyrrolidine-1-sulfonamide; (S)-N-(((S)-1,4-dioxan-2-yl)methyl)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)-amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (2R,3S)-3-((9-ethyl-6-(((S)-1-((3-fluoroazetidin-1-yl)sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; 291 (S)-N-(((R)-1,4-dioxan-2-yl)methyl)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)-amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (3R*,4R*)-3-((2-(((R)-1-cyclopropyl-2-hydroxyethyl)amino)-9-methyl-9H-purin-6-yl)-amino)-N-ethyl-4-fluoropyrrolidine-1-sulfonamide; (R)-2-(6-((S)-1-(cyclopropylsulfonyl)pyrrolidin-3-yl)amino)-9-isopropyl-9H-purin-2-ylamino)-3-methylbutan-1-ol; (R)-2-(9-ethyl-6-((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-(9-cyclopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl-amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-cyclopropyl-2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)ethanol; (2R,3S)-3-((9-isopropyl-6-(((S)-1-(1-methyl-1H-pyrazol-4-yl-sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; (2R,3S)-3-((9-isopropyl-6-(((S)-1-(1-methyl-1H-imidazol-4-yl-sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; (R)-2-((6-(((3R,4R)-4-fluoro-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9-isopropyl-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-isopropyl-6-(((3S,5R)-5-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-isopropyl-6-(((3S,5S)-5-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-isopropyl-6-(((3S,4R)-4-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (2R,3S)-3-((9-isopropyl-6-(((3S,5R)-5-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; 292 (R)-2-((9-ethyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)butan-1-ol; (R)-2-cyclopropyl-2-((9-ethyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)ethanol; (R)-2-((9-ethyl-6-(((S)-1-(2,2,2-trifluoroethylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((6-(((S)-1-(cyclopropylsulfonyl)pyrrolidin-3-yl)amino)-9-ethyl-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-ethyl-6-(((S)-1-((2-methoxyethyl)sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-ethyl-6-(((S)-1-(fluoromethylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-hydroxy-2-methylpentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-hydroxy-2-methylpentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-1-hydroxybutan-2-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R*,3S*)-4,4,4-trifluoro-3-hydroxybutan-2-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; 293 (3R*,4R*)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-4-fluoro-N-methylpyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9-methyl-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-3-((9-(fluoromethyl)-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-(difluoromethyl)-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (2R,3S)-3-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoropyrrolidin-3-yl)-amino)-9-methyl-9H-purin-2-yl)amino)pentan-2-ol; (2R,3S)-3-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoropyrrolidin-3-yl)-amino)-9-(difluoromethyl)-9H-purin-2-yl)amino)-1,1,1-trifluorobutan-2-ol; (S)-3-((2-(((R*)-1-cyclopropyl-3-hydroxypropan-2-yl)amino)-9-ethyl-9H-purin-6-yl)-amino)-N-ethylpyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((R*)-3-hydroxy-3-methylbutan-2-yl)-amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((3-ethyl-5-(((2R,3S)-2-hydroxypentan-3-yl)amino)-3H-imidazo[4,5-b]pyridin-7-yl)amino)pyrrolidine-1-sulfonamide; (R)-2-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoro-pyrrolidin-3-yl)amino)-9-(difluoromethyl)-9H-purin-2-yl)amino)-2-cyclopropylethan-1-ol; and (2R,3S)-3-((6-(((S)-1-((1H-pyrazol-5-yl)sulfonyl)pyrrolidin-3-yl)amino)-9-ethyl-9H-purin-2-yl)amino)pentan-2-ol.
19. A pharmaceutical composition comprising a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 294
20. A method of treating cancer in a subject suffering from or susceptible to the cancer, the method comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof.
21. The method of claim 20, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, endometrial cancer, cervical cancer, uterine cancer, gastric cancer, prostate cancer, bladder cancer, lung cancer, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, pancreatic cancer, thyroid cancer, colorectal cancer, and skin cancer.
22. The method of claim 20 or 21, wherein the method further comprises administering to the subject a therapeutically effective amount of a CDK4/6 inhibitor.
23. The use of a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer.
IL321433A 2022-12-16 2023-12-15 2,6,9-trisubstituted purines IL321433A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263387734P 2022-12-16 2022-12-16
PCT/IB2023/062789 WO2024127350A1 (en) 2022-12-16 2023-12-15 2,6,9-trisubstituted purines

Publications (1)

Publication Number Publication Date
IL321433A true IL321433A (en) 2025-08-01

Family

ID=89473830

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321433A IL321433A (en) 2022-12-16 2023-12-15 2,6,9-trisubstituted purines

Country Status (17)

Country Link
US (2) US20240247001A1 (en)
EP (1) EP4634186A1 (en)
JP (1) JP2026500305A (en)
KR (1) KR20250121114A (en)
CN (1) CN120359223A (en)
AR (1) AR131380A1 (en)
AU (1) AU2023393410A1 (en)
CL (1) CL2025001706A1 (en)
CO (1) CO2025009649A2 (en)
CR (1) CR20250283A (en)
DO (1) DOP2025000143A (en)
IL (1) IL321433A (en)
MX (1) MX2025006884A (en)
PE (1) PE20251925A1 (en)
TW (1) TWI922868B (en)
UY (1) UY40564A (en)
WO (1) WO2024127350A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025202991A1 (en) * 2024-03-29 2025-10-02 Astrazeneca Ab Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl)amino)-pyrrolidine-1-sulfonamide
WO2026012471A1 (en) * 2024-07-11 2026-01-15 上海先声再明医药生物科技有限公司 Substituted purine compound and use thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
CN119462661A (en) * 2024-09-24 2025-02-18 烟台皓元生物医药科技有限公司 A preparation method of AZD-8421 and its intermediates

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432164A (en) 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
DE19653646A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
IL144675A0 (en) 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2793794B1 (en) 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc NOVEL PURINE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NEW USE
CZ2002961A3 (en) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamides and related compounds for factor Xa inhibition
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
EP1377579B1 (en) 2000-10-31 2009-03-25 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2002334992B2 (en) 2001-10-12 2009-07-02 Irm Llc Methods for the synthesis of substituted purines
JP2005535631A (en) 2002-06-27 2005-11-24 エフ.ホフマン−ラ ロシュ アーゲー Synthesis of purine derivatives
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
JP2007502776A (en) 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー 6-Substituted anilinopurines as RTK inhibitors
MXPA06013250A (en) 2004-05-14 2007-02-28 Abbott Lab Kinase inhibitors as therapeutic agents.
JP2006056879A (en) 2004-07-21 2006-03-02 Kobe Univ Insulin resistance improving agent and screening method thereof
US7514417B2 (en) 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
BRPI0614502A2 (en) 2005-07-30 2011-03-29 Astrazeneca Ab COMPOUND, PROCESS TO PREPARE THE SAME, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
WO2007028022A2 (en) 2005-09-01 2007-03-08 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
GB0606283D0 (en) 2006-03-29 2006-05-10 Cyclacel Ltd Process
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
CA2676138A1 (en) 2007-01-26 2008-08-07 Irm Llc Compounds and compositions as kinase inhibitors
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
WO2009129094A2 (en) 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
US20130137728A1 (en) 2010-03-24 2013-05-30 MUSC Foundation for Research and Development Compositions and Methods for the Treatment of Degenerative Diseases
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
JP2013540145A (en) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス Selective CYP11B1 inhibitor for the treatment of cortisol-dependent diseases
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
DK2753605T3 (en) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc COMPOSITIONS, METHODS AND SYSTEMS FOR THE SYNTHESIS AND THE APPLICATION OF IMAGE CRAFTS
US9187480B2 (en) 2012-02-17 2015-11-17 Research Triangle Institute Peripherally restricted diphenyl purine derivatives
RU2661896C2 (en) 2012-11-16 2018-07-23 Мерк Шарп И Доум Корп. Purine inhibitors of human phosphatidylinositol 3-kinase delta
US20140275178A1 (en) 2013-03-13 2014-09-18 Musc Foundation For Research Development Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
US9796714B2 (en) 2013-05-20 2017-10-24 University of Pittsburgh—of the Commonwealth System of Higher Education Calcium channel agonists
WO2016011394A1 (en) 2014-07-18 2016-01-21 The General Hospital Corporation Imaging agents for neural flux
CN107427521B (en) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 Inhibitors of cyclin-dependent kinases
US20180000814A1 (en) 2016-06-14 2018-01-04 Joseph Hacia Compositions and methods for the treatment of zellweger spectrum disorder
WO2018036414A1 (en) 2016-08-23 2018-03-01 北京诺诚健华医药科技有限公司 Fused heterocyclic derivative, preparation method therefor and medical use thereof
KR101893879B1 (en) 2017-03-31 2018-09-03 한국화학연구원 Novel CDK inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating CDK relating diseases containing the same as an active ingredient
US20190029977A1 (en) 2017-04-24 2019-01-31 Mercaptor Discoveries, Inc. Use of Thiol Compounds to Treat Neurological Disease
CN110582496A (en) 2017-05-03 2019-12-17 格勒诺布尔-阿尔卑斯大学 Methods for the synthesis of variously substituted purines
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
JP2021536458A (en) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. Aryl Hydrocarbon Receptor Antagonists and Usage
JP2022506682A (en) 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ,インコーポレーテッド Compound
JP7594787B2 (en) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア Non-ATP/catalytic site p38 mitogen-activated protein kinase inhibitors
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
CN113692276B (en) 2019-02-19 2026-02-27 加利福尼亚大学董事会 NURR1 receptor modulators
WO2020181050A1 (en) 2019-03-05 2020-09-10 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN111825674A (en) 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 Pyrimido five-membered heterocyclic compounds and their use as mutant IDH2 inhibitors
CN114025758B (en) 2019-07-01 2026-05-08 钱立刚 P2X7R antagonist
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN113024563B (en) 2019-12-24 2023-01-03 药康众拓(江苏)医药科技有限公司 Pyrimido five-membered heterocyclic compound or pharmaceutically acceptable salt and isomer thereof, and preparation method, pharmaceutical composition and application thereof
US20230140941A1 (en) 2020-03-13 2023-05-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
JP2021167301A (en) 2020-04-08 2021-10-21 ファイザー・インク Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
US12653888B2 (en) 2020-05-04 2026-06-16 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing immune responses to infectious agents
JP7853532B2 (en) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー/エス Cyclin-dependent kinase inhibitor compounds for treating medical disorders
US20260167619A2 (en) 2020-09-22 2026-06-18 Beone Medicines I Gmbh Indoline compounds and derivatives as egfr inhibitors
CN122562781A (en) 2020-10-07 2026-08-14 上海睿跃生物科技有限公司 Compounds and methods for treating cancer
EP4284415A4 (en) 2021-01-26 2024-12-11 Sigilon Therapeutics, Inc. BIOCOMPATIBLE DEVICES FOR CELLULAR THERAPIES AND RELATED METHODS
CN116981473A (en) 2021-01-26 2023-10-31 西吉隆医疗股份有限公司 Compositions, devices and methods for treating immune-mediated inflammatory diseases
US20240374507A1 (en) 2021-01-26 2024-11-14 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing antigen-specific immune tolerance
WO2022266190A1 (en) 2021-06-16 2022-12-22 Blueprint Medicines Corporation Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors
CN117897384A (en) 2021-06-28 2024-04-16 缆图药品公司 CDK2 inhibitors
CN116813621A (en) 2023-06-08 2023-09-29 江南大学 9H purine compounds and pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
EP4634186A1 (en) 2025-10-22
WO2024127350A1 (en) 2024-06-20
TWI922868B (en) 2026-04-21
KR20250121114A (en) 2025-08-11
US20240247001A1 (en) 2024-07-25
JP2026500305A (en) 2026-01-06
PE20251925A1 (en) 2025-08-05
CN120359223A (en) 2025-07-22
US12441744B2 (en) 2025-10-14
MX2025006884A (en) 2025-07-01
UY40564A (en) 2024-06-28
AR131380A1 (en) 2025-03-12
CO2025009649A2 (en) 2025-08-08
TW202440578A (en) 2024-10-16
CR20250283A (en) 2025-08-21
CL2025001706A1 (en) 2025-08-18
US20250197425A1 (en) 2025-06-19
DOP2025000143A (en) 2025-08-15
AU2023393410A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
JP2022545542A5 (en)
JP7713934B2 (en) Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
TWI831803B (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2022533260A5 (en)
RU2010137635A (en) HETEROCYCLIC ANTI-VIRAL COMPOUNDS
JP2023531390A (en) Phthalazinone compound, its preparation method and its medical use
US12338249B2 (en) Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea
ES2953834T3 (en) Novel phthalazinone derivatives and their manufacturing procedure
IL295456A (en) Heterocyclic compounds for nr2f6 modulation
IL275649B1 (en) Irak degraders and uses thereof
KR960702838A (en) Use of INDOLOCARBAZOLE derivatives in the treatment of the pathological condition of the prostate gland
CN110291097A (en) Steroid compounds and protein-conjugates thereof
US12441744B2 (en) 2,6,9-trisubstituted purines
RU2010153578A (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION
JP2023504187A5 (en)
US20240174615A1 (en) Synthesis of rapamycin analog compounds
AU2022316425A1 (en) Drug conjugate of eribulin derivative
US20230135729A1 (en) Compound with anti-spore activity and pharmaceutical composition thereof
CN114644635B (en) Triazole tricyclic derivatives, preparation method and application thereof
CN114989156B (en) Receptor interaction protein inhibitor and preparation method and application thereof
NZ728685A (en) New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
NZ728685B2 (en) New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
HK40104808A (en) Fused ring compound as protein degradation agent as well as preparation method and use thereof
WO2026041050A1 (en) Ligand-protein degrader conjugate and pharmaceutical use thereof
TW202543607A (en) Interlukin-17a inhibitors and uses thereof